The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.

Regional Hospital Holstebro

Status and phase: Completed; Phase 4

Conditions: Healthy

Treatments: Drug: Eprosartan

Study type: Interventional

Funder types: Other

Identifiers

NCT00409903

MED.RES.HOS.2006.02.HV

Details and patient eligibility

About

We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in healthy individuals - during baseline conditions and after activation of the sympathetic nervous system.

Enrollment: 18 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Both genders.
• Age 18 - 65 years.
• Body mass index less or equal to 30 kg/m2.
• Women must use oral hormonal anticonception, use intrauterine anticonceptive device, be sterilized/hysterectomized or be postmenopausal.

Exclusion criteria

• History or clinical signs of heart, lung, kidney, or endocrine organ disease.
• Abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine, P-albumin, P-bilirubin, P-alanine aminotransferase, P-alkaline phosphatase, P-cholesterol, and B-glucose.
• Abnormal screening of the urine regarding: albumin and glucose
• Malignant disease.
• Known arterial hypertension or measured 24 hour blood pressure above 135 mmHg systolic or 85 mmHg diastolic.
• Alcohol abuse.
• Smoking.
• Drug use or abuse.
• Known intolerance or allergy to eprosartan or sodium nitroprusside.
• Blood donation within 1 month of the start of the study.